Potential of Using Cannabidiol as a Therapeutic Molecule Against Various Cell Signaling Molecules Involved in Breast Cancer Complications: A Bioinformatics Approach.

BACKGROUND Breast cancer progression involves key processes such as uncontrolled cell proliferation, resistance to apoptosis, metastasis, and angiogenesis. Cannabidiol (CBD), a non-psy-choactive compound from Cannabis sativa, has shown promise for its anti-cancer properties. This study aimed to explore the interaction of CBD with proteins involved in these processes. METHODS Molecular docking was performed to assess the binding affinity of CBD to four critical proteins: CDK6 (cell cycle regulator), BCL2 (anti-apoptotic protein), MMP2 (invasion-related en-zyme), and VEGFR2 (angiogenesis-related receptor). Known inhibitors, palbociclib, ABT-199, doxycycline, and axitinib, were used as reference compounds for comparison. RESULTS Cannabidiol exhibited strong binding affinities for CDK6, BCL2, MMP2, and VEGFR2. The docking scores were comparable to those of the respective standard inhibitors, suggesting effec-tive interactions with the active sites of the target proteins. DISCUSSION These findings suggest that CBD may simultaneously target multiple cancer-related pathways, offering a potential multi-target therapeutic approach for breast cancer. Its comparable efficacy to standard inhibitors, combined with a favorable safety profile, supports its potential for further development. However, experimental validation through in vitro and in vivo studies is neces-sary to confirm its therapeutic effectiveness. CONCLUSION CBD demonstrates promising multi-target activity against critical signaling molecules in breast cancer and may serve as a safer, natural therapeutic candidate. Further preclinical and clin-ical investigations are warranted.